Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : EntreMed (ENMD) -- Ignore unavailable to you. Want to Upgrade?

To: drsvelte who wrote (555)	5/4/1998 5:21:00 PM
From: Tech Master	Read Replies (1) \| Respond to of 2135

TAKE YOUR PROFITS PEOPLE... this is a CYA press release because the company knows that the stock is WAY ahead of itself. Monday May 4, 4:26 pm Eastern Time Company Press Release EntreMed Inc. Issues Statement Regarding Angiostatin-TM Protein and Endostatin-TM Protein ROCKVILLE, Md.--(BW HealthWire)--May 4, 1998--In response to recent press reports regarding the status of the development of two proteins, Angiostatin(TM) protein and Endostatin(TM) protein, which are effective in treating cancerous tumors in mice, EntreMed Inc. (Nasdaq:ENMD - news) cautioned that the development efforts remain at a preclinical stage and that it will likely take approximately 12 to 18 months before either of these proteins is tested in Phase I clinical trials in humans. If the Phase I clinical trial is successful, further FDA approved clinical trials would then be required before either protein could receive all necessary regulatory approvals. Consequently, no assurance can be given that either of these proteins will prove to be effective in humans. EntreMed is very pleased with the progress of these proteins to date and applauds the work of Dr. M. Judah Folkman and his colleagues at Children's Hospital, a teaching affiliate of the Harvard Medical School in Boston, as well as the efforts being made by the National Cancer Institute (NCI). EntreMed scientists are working diligently to complete the preclinical studies needed to allow filing of an Investigational New Drug Application (''INDA'') for Endostatin(TM) protein. Further, the Company is collaborating closely with its partner, Bristol-Myers Squibb Company (NYSE:BMY - news), regarding preclinical studies with Angiostatin(TM) protein. Rockville, Md.-based EntreMed Inc., an innovative biopharmaceutical company, is a leader in the field of antiangiogenesis research, which involves the inhibition of abnormal blood vessel growth believed to be associated with a broad range of diseases. The Company's strategy is to accelerate development of its current core technologies through collaborations and sponsored research programs with university medical facilities, research companies and government laboratories. In December 1995, EntreMed forged a strategic partnership with Bristol-Myers Squibb Company to further the preclinical and clinical development of Angiostatin(TM) protein and thalidomide analogs.

To: drsvelte who wrote (555)	5/4/1998 5:33:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 2135

drsvelte: I've met one of the V.P.s (Dan Witt) in two different professional circumstances, once as a potential collaborator while I was at SyStemix and once as a consultant sniffing them out last Spring. I met their second V.P. (Jim Rusche) last Summer at an IBC conference on angio (highly recommended, BTW). I like them. I also toured the facility last Spring. I've owned them now since last Spring, and, if you look at a chart, you'll see that I'm pleased with their performance. I sold PGEN into today's strength, but I kept my RGEN and SUGN. Cheers! Rick